In response to a letter from a group of cross-party MEPs calling for the EU to act fast on psychedelics, the European Medicines Agency will be...
Biopharmaceutical company Cybin has selected generalised anxiety disorder (GAD), with or without major depressive disorder (MDD), as the target indication for its proprietary deuterated DMT molecule,...
Silo Pharma is advancing its clinical study exploring psilocybin’s effect on inflammation, targeting conditions such as Parkinson’s disease, bipolar disorder and chronic pain.
Awakn Life Sciences has announced the signing of a five-year lease to open a larger Awakn Clinics Oslo.
Canadian pharmaceutical development company Algernon Pharmaceuticals has commenced screening subjects for its Phase 1 clinical study of an intravenous formulation of DMT – AP-188 – in...
Cybin has now dosed the first patients in its Phase 1/2a trial clinical trial investigating in psilocybin analogue CYB003 for the treatment of major depressive disorder...
The hallucinogenic effect of psychedelics may hold much healing potential, but researchers believe that these compounds could be beneficial for brain disorders without hallucinations.
MAPS PBC is entering into a collaboration that aims to bring its novel therapy for PTSD closer to regulatory evaluation.
Christie’s is presenting its Non-Fungible Token (NFT) auction – ‘Cartography of the Mind’ – to raise funds for the Multidisciplinary Association for Psychedelic Studies (MAPS).
The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals.
